Press coverage about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cardiome Pharma earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.1213785203357 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Cardiome Pharma stock traded up $0.01 during trading hours on Thursday, hitting $2.38. 17,768 shares of the stock were exchanged, compared to its average volume of 155,271. The company has a current ratio of 4.80, a quick ratio of 3.99 and a debt-to-equity ratio of 2.47. The stock has a market capitalization of $83.69, a price-to-earnings ratio of -2.63 and a beta of 0.22. Cardiome Pharma has a 12 month low of $1.29 and a 12 month high of $4.84.

Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last issued its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.05). The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.94 million. Cardiome Pharma had a negative return on equity of 123.36% and a negative net margin of 124.17%. equities research analysts predict that Cardiome Pharma will post -0.77 EPS for the current year.

Several analysts have weighed in on the stock. HC Wainwright set a $10.00 price objective on shares of Cardiome Pharma and gave the stock a “buy” rating in a research note on Wednesday, April 4th. Canaccord Genuity set a $5.00 price objective on shares of Cardiome Pharma and gave the stock a “buy” rating in a research note on Wednesday, March 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $5.67.

TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/04/19/cardiome-pharma-crme-getting-somewhat-positive-news-coverage-study-finds-2.html.

Cardiome Pharma Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Insider Buying and Selling by Quarter for Cardiome Pharma (NASDAQ:CRME)

Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.